Search

Ocular Therapeutix Inc

Chiusa

SettoreSettore sanitario

10.64

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

10.59

Massimo

10.74

Metriche Chiave

By Trading Economics

Entrata

9.8M

-79M

Vendite

2.7M

13M

EPS

-0.35

Margine di Profitto

-584.512

Dipendenti

325

EBITDA

10M

-74M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+142.29% upside

Dividendi

By Acuity

Utili prossimi

3 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

383M

2.3B

Apertura precedente

10.64

Chiusura precedente

10.64

Notizie sul Sentiment di mercato

By Acuity

29%

71%

62 / 339 Classifica in Healthcare

Ocular Therapeutix Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 set 2026, 20:01 UTC

Ocular Therapeutix Inc's shares are lower today, breaking a trend of higher closes since Wednesday. No specific news was identified to explain the decline.

2 set 2026, 23:31 UTC

Ocular Therapeutix shares were roughly flat in after-market hours. The broader market reacted to a weaker-than-expected ADP payrolls report.

1 set 2026, 19:46 UTC

Ocular Therapeutix Inc's shares are higher today, rebounding from earlier volatility and remaining well above the 20-day moving average.

31 ago 2026, 21:01 UTC

Ocular Therapeutix Inc is trading higher in after-market hours, showing strength despite broader market pressure from hawkish Fed remarks. No specific news was identified.

28 ago 2026, 20:08 UTC

Ocular Therapeutix Inc shares are lower today, reflecting broader market declines amid rising U.S. Treasury yields and inflation concerns. No specific company news was identified.

27 ago 2026, 21:01 UTC

Ocular Therapeutix Inc shares are trading lower in after-market hours. No specific company news was identified to explain this movement.

26 ago 2026, 19:36 UTC

Ocular Therapeutix Inc shares are lower today, with no specific news identified. This follows U.S. PCE data indicating inflationary pressures.

24 ago 2026, 20:06 UTC

Social Media

Ocular Therapeutix Inc. shares are lower amid a lawsuit from EyePoint, Inc. and broader market pressures, despite a brief rebound earlier in the session.

22 ago 2026, 00:02 UTC

Ocular Therapeutix Inc is trading higher in after-market hours, maintaining momentum from Friday's close amid a broadly positive market performance.

21 ago 2026, 21:01 UTC

Ocular Therapeutix Inc shares are higher in after-market trading, reflecting strong performance amid positive sentiment in related sectors and developments in the cryptocurrency market.

20 ago 2026, 20:02 UTC

Ocular Therapeutix Inc is lower today amid broader market declines following Walmart's disappointing sales growth and guidance, contributing to increased selling pressure.

19 ago 2026, 23:21 UTC

Ocular Therapeutix Inc shows modest gains in after-market trading, with no specific news identified for the price movement. The stock remains above its 20-day moving average.

18 ago 2026, 22:26 UTC

Social Media

Ocular Therapeutix shares rise in after-market hours after Cowen set a $20 price target, and Baird raised its target to $30 amid competitive advantages.

17 ago 2026, 23:11 UTC

Ocular Therapeutix Inc's shares are higher in after-market trading, continuing a strong performance since Monday's close and reaching a notable high.

14 ago 2026, 19:46 UTC

Ocular Therapeutix Inc shares are lower amid a decline in the Pharmaceuticals sub-sector. The stock has traded down since Thursday's close.

13 ago 2026, 23:16 UTC

Ocular Therapeutix Inc's shares are lower in after-market hours, reflecting a slight decline since Thursday's close. No specific news was identified for this movement.

12 ago 2026, 20:01 UTC

Ocular Therapeutix Inc shares are higher in Wednesday's session, with elevated trading volume. The stock remains above its 20-day moving average.

11 ago 2026, 23:21 UTC

Ocular Therapeutix Inc shares fell during after-market hours, reaching a session low before slightly recovering. Broader market dynamics may be influencing this decline.

10 ago 2026, 20:06 UTC

Ocular Therapeutix Inc is trading higher, recovering above its 20-day moving average amid a broader trend of three consecutive sessions finishing higher.

7 ago 2026, 21:01 UTC

Ocular Therapeutix Inc shares are higher in after-market hours, continuing an upward trend after three consecutive sessions of gains.

6 ago 2026, 20:06 UTC

Ocular Therapeutix Inc shares are higher during Thursday's session, recovering from an earlier dip despite trading below their 20-day moving average.

5 ago 2026, 21:03 UTC

Ocular Therapeutix Inc shares are lower in after-market trading, with no specific news identified to explain the decline. The stock remains under pressure.

3 ago 2026, 20:06 UTC

Social Media
News

Ocular Therapeutix shares rise after reporting Q2 revenue of $13.5 million, exceeding estimates, and announcing plans for a new drug application for AXPAXLI.

31 lug 2026, 21:01 UTC

Ocular Therapeutix Inc shares are lower in after-market hours with no specific news identified. Broader market conditions reflect mixed performance amid rising inflation concerns.

30 lug 2026, 19:39 UTC

Ocular Therapeutix shares are higher today, continuing an upward trend since Wednesday. The U.S. Dollar Index decline may be influencing broader market dynamics.

28 lug 2026, 19:06 UTC

News

Ocular Therapeutix shares are lower amid broader market volatility and regulatory challenges, reaching a session low earlier today.

27 lug 2026, 21:01 UTC

Ocular Therapeutix Inc. shares are higher in after-market trading, reaching a peak shortly after the session began amid improved European market sentiment.

22 lug 2026, 18:36 UTC

Social Media

Ocular Therapeutix is presenting at the HC Wainwright conference, but shares are declining and remain below their 20-day moving average.

21 lug 2026, 23:41 UTC

Ocular Therapeutix Inc shares rose in after-market trading, reaching their highest cumulative return of the day. The stock remains below its 20-day moving average.

20 lug 2026, 19:46 UTC

Social Media

Ocular Therapeutix shares are lower today, continuing a downward trend. Early gains were followed by a pullback amid uncertain investor sentiment.

Confronto tra pari

Modifica del prezzo

Ocular Therapeutix Inc Previsione

Obiettivo di Prezzo

By TipRanks

142.29% in crescita

Previsioni per 12 mesi

Media 25.78 USD  142.29%

Alto 31 USD

Basso 18 USD

Basato su 10 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Ocular Therapeutix Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

10 ratings

10

Acquista

0

Mantieni

0

Vendi

Sentiment

By Acuity

62 / 339 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
help-icon Live chat